Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation (RGEN) drives innovation in bioprocessing technologies critical for biologics manufacturing, serving pharmaceutical companies and CDMOs worldwide. This page provides investors and industry professionals with timely updates on corporate developments shaping the life sciences sector.
Access comprehensive coverage of Repligen's strategic initiatives, including financial results, product innovations, and partnership announcements. Our curated news collection enables stakeholders to track the company's impact on biomanufacturing efficiency and therapeutic development pipelines.
Explore updates across key operational areas: quarterly earnings disclosures, regulatory milestones for filtration systems and chromatography products, R&D advancements in process analytics, and global expansion efforts. Content is rigorously verified to ensure alignment with market-moving developments.
Bookmark this page for streamlined access to Repligen's evolving market position. Regularly updated coverage supports informed analysis of the company's role in advancing next-generation drug manufacturing technologies.
Repligen Corporation (NASDAQ:RGEN) will announce its first quarter 2023 financial results on May 2, 2023, before the market opens. A conference call is scheduled for 8:30 a.m. ET to discuss business updates and financial results for the quarter ending March 31, 2023. Investors can join the call by dialing (844) 274-3999 (U.S.) or (412) 317-5607 (international) without a passcode. A webcast will also be available on the Company’s Investor Relations page. Repligen specializes in bioprocessing technologies for biopharmaceutical manufacturing.
Repligen Corporation (NASDAQ:RGEN) announced its participation in the KeyBanc Life Science and MedTech Investor Forum on March 21-22, 2023. CEO Tony J. Hunt will lead an analyst-led discussion on March 21 at 1:30 p.m. EDT. A live webcast of the presentation will be available on the Company's Investor Relations website and will be accessible for replay after the event. Repligen specializes in bioprocessing technologies, aiming to improve the manufacturing efficiency of biological drugs for biopharmaceutical developers and contract organizations globally. The company operates in various locations, primarily within the U.S., and has a strong presence in multiple European countries.
Repligen Corporation (NASDAQ:RGEN) reported strong financial results for the fourth quarter and full year 2022. Fourth quarter revenue reached $186.8 million, marking 4% organic growth year-over-year, while full-year revenue totaled $801.5 million, a 22% organic growth. The base business demonstrated impressive organic growth of 35% in Q4 and 39% for the year. Despite these achievements, gross profit decreased in Q4 by 9%, impacted by declining COVID-related product revenues and increased costs. Looking ahead, Repligen expects 2023 total revenue between $760-$800 million, anticipating a reduction in COVID-related revenue and gross margin decline to 52.5%-53.5%.
FAQ
What is the current stock price of Repligen (RGEN)?
What is the market cap of Repligen (RGEN)?
